Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study

Autor(es)

Ambati, A. ^{[1, 2]} ; Boas, L. S. V. ^[3] ; Ljungman, P. ^{[1, 4]} ; Testa, L. ^[5] ; de Oliveira, J. F. ^[6] ; Aoun, M. ^[7] ; Colturato, V. ^[5] ; Maeurer, M. ^{[7, 2]} ; Machado, C. M. ^{[3, 5]}

Afiliação do(s) autor(es)

^[1] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm - Sweden

^[2] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat CAST, Stockholm - Sweden

^[3] Univ Sao Paulo, Inst Trop Med, Virol Lab LIM HCFMUSP 52, BR-05403000 Sao Paulo - Brazil

^[4] Karolinska Univ Hosp, Dept Hematol, Stockholm - Sweden

^[5] Amaral Carvalho Fdn, Hematopoiet Stem Cell Transplant Program, Jahu - Brazil

^[6] Univ Fed Minas Gerais, Clin Hosp Sch Med, Belo Horizonte, MG - Brazil

^[7] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol TIM, Stockholm - Sweden

• Tipo de documento: Artigo Científico
• Fonte: BONE MARROW TRANSPLANTATION; v. 50, n. 6, p. 858-864, JUN 2015.
• Citações Web of Science: 12

Resumo

Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n = 38), donor pretransplant vaccination (n = 44) or recipient pretransplant vaccination (n = 40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (P<0.001) compared with the other groups at the time of donation. The titers against H1 (P = 0.028) and H3 (P<0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P = 0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates. (AU)

• Processo FAPESP: 08/00282-8 - Estudo da eficácia e da imunogenicidade de esquemas alternativos de vacinação contra a influenza em receptores de tcth
• Beneficiário: Clarisse Martins Machado
• Modalidade de apoio: Auxílio à Pesquisa - Regular